Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin vs Doxorubicin-based Chemotherapy in Translocation-Related Sarcomas
NCT00796120Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2008
- Primary completion
- Aug 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of trabectedin in translocation-related sarcoma (TRS), sponsored by Johnson & Johnson. Started Nov 2008; status: completed.
02
Drugs
trabectedin
03
Conditions
translocation-related sarcoma (TRS)
Beyond the preview
Go deeper on NCT00796120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796120.